Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time -0:00
1x
- 0.5x
- 0.75x
- 1x, selected
- 1.25x
- 1.5x
- 1.75x
- 2x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
10 seconds
Playback speed
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Recent Studies on Safety of PDE-5 Inhibitors with Antihypertensive Medicines and Nitrates: Should Nitrates Remain a Contraindication or Now Be Considered a Warning?
134 views
July 11, 2023
Speaker Name and Title: Peter Ganz MD
The Princeton 4 meeting was sponsored by an ...
read more ↘ unrestricted grant from Sanofi.
Sanofi was not involved in choosing the content or speakers for the meeting.
Affiliation of the speaker:
Zuckerberg San Francisco General Hospital and University of California, San Francisco
Title of the speaker’s talk: “Recent studies on safety of PDE-5 inhibitors with antihypertensive medicines and nitrates. Should nitrates remain a contraindication or now be considered a warning?”
Financial disclosure/Conflict of Interest:
- Dr. Ganz serves on the medical advisory board of SomaLogic, a proteomics company, for which he accepts no financial remuneration of any kind.
- Dr. Ganz is a Scientific Advisor to Riparian Pharma, which is developing a pharmacological agent to reverse endothelial dysfunction.
↖ read less
The Princeton 4 meeting was sponsored by an ...
read more ↘ unrestricted grant from Sanofi.
Sanofi was not involved in choosing the content or speakers for the meeting.
Affiliation of the speaker:
Zuckerberg San Francisco General Hospital and University of California, San Francisco
Title of the speaker’s talk: “Recent studies on safety of PDE-5 inhibitors with antihypertensive medicines and nitrates. Should nitrates remain a contraindication or now be considered a warning?”
Financial disclosure/Conflict of Interest:
- Dr. Ganz serves on the medical advisory board of SomaLogic, a proteomics company, for which he accepts no financial remuneration of any kind.
- Dr. Ganz is a Scientific Advisor to Riparian Pharma, which is developing a pharmacological agent to reverse endothelial dysfunction.
↖ read less
Comments 0
Login to view comments.
Click here to Login